Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. (Abbreviated as: Tri-Prime Gene; Stock Code: 837344), with a registered capital of RMB 121.81 million, is a leading enterprise specializing in the research and development, production, and commercialization of modern biopharmaceuticals in China. The company has been long established as an industry pioneer in both fundamental research and clinical application development of genetically engineering drugs.

Founded in 1992, Tri-Prime Gene holds the distinction of being China's first pharmaceutical company being named for its proprietary genetically engineering technologies. It was co-founded by its inaugural Chairman, Academician Hou Yunde, and inaugural General Manager, Mr. Cheng Yongqing. The company's core product, Recombinant Human Interferon α1b (Hapgen®), represents China's first Class I genetically engineered novel drug with independent intellectual property rights, indicated for the treatment of various viral diseases and malignant tumors. Marketed under the brand name Hapgen®, this product has become a premium therapeutic brand in China's genetically engineering drug market, delivering significant economic and social benefits.

With robust R&D capabilities, Tri-Prime Gene has been a postdoctoral research center since 2001 being approved by China's Ministry of Personnel. The company's development pipeline includes several clinical-stage novel drug candidates achieving global standards of innovation. Tri-Prime Gene holds 50+ patents in China, the United States, and other countries. Tri-Prime Gene has undertaken more than 20 national and municipal key scientific research projects, and has obtained 10+ new drug certificates and production approvals, demonstrating its strong innovation capabilities and industry-leading position.